On the other hand, the increased expression of MYH2 in COPD patients may reflect a disease-specific adaptive remodeling of skeletal muscle, supporting its role as a complementary diagnostic marker for COPD-related NAFLD (31–33). The gene discussed is MYH2; the disease is metabolic dysfunction-associated steatotic liver disease.